Introduction
============

Tuberculosis remains a major cause of death worldwide despite a decline in incidence in recent years ([@b1-etm-0-0-4737]). It is estimated that there were 9.6 million new cases of tuberculosis and 1.5 million cases of tuberculosis-associated mortality in 2014. China, one of nine high-burden countries of tuberculosis, had 10% of the global total TB cases ([@b2-etm-0-0-4737]). Although the majority of exposed individuals have asymptomatic latent tuberculosis, they are at increased risk of developing active tuberculosis and becoming infectious ([@b3-etm-0-0-4737]). Asymptomatic pulmonary tuberculosis (PTB) exhibits various clinical and radiological features that resemble a number of other diseases ([@b4-etm-0-0-4737],[@b5-etm-0-0-4737]). Cases of PTB that mimic lung cancer are encountered on occasion. According to a report from National Central Cancer Registry of China, there were 651,053 newly diagnosed cases of lung cancer in 2011 in China, and 529,153 patients died of lung cancer with a crude incidence and mortality of 48.32 per 100,000 population and 39.27 per 100,000 population, respectively ([@b6-etm-0-0-4737],[@b7-etm-0-0-4737]). Due to the increasing incidence and mortality of lung cancer, it has become the leading cause of cancer-related death in China ([@b8-etm-0-0-4737]). The clinical symptoms and radiologic features of PTB are nonspecific and resemble lung cancer, therefore accurate diagnosis of these two diseases remain a diagnostic dilemma in the clinic ([@b9-etm-0-0-4737]--[@b13-etm-0-0-4737]).

Typical manifestations of PTB are generally easy to diagnose due to defined clinical characteristics and radiographic findings. However, many symptoms of PTB, including cough, hemoptysis and weight loss are also common in lung cancer ([@b14-etm-0-0-4737]). Meanwhile, typical radiographic features indicating lung cancer, including thick-walled cavities and high fluorodeoxyglucose (FDG) uptake are also seen in PTB ([@b11-etm-0-0-4737]), and so patients exhibiting asymptomatic PTB mimicking lung cancer are often misdiagnosed with lung cancer. The misdiagnosis may result in delayed treatment for PTB and unnecessary operations, further increasing the severity and complications of PTB ([@b15-etm-0-0-4737],[@b16-etm-0-0-4737]). Therefore, the present study was conducted in order to identify the features of this unusual PTB and improve the diagnostic accuracy.

Patients and methods
====================

### Patients

A total of 1,487 individuals at Chinese PLA General Hospital (Beijing, China) were consecutively enrolled in the current study between January 2011 and December 2015. These individuals were included as they underwent a periodic health examination and an indeterminate lung nodule or mass was detected by chest X-ray. A total of 241 individuals were initially excluded due to the following reasons: 138 did not undergo further examination, 45 exhibited symptoms of PTB or lung cancer, 39 had a history of cancer or tuberculosis, 16 had undergone thoracic surgery in the past 6 months and 3 were \<18 years old. Out of the 1,246 individuals who subsequently underwent chest computer tomography (CT) or whole-body 18F-fludeoxyglucose-positron emission tomography-computer tomography (PET-CT), 226 were presumptively diagnosed with lung cancer. No pathological examinations were performed in 112 individuals, the data for 7 individuals was missing and 4 individuals tested negative for lung cancer or PTB; these patients were all excluded. Therefore, 22 patients with PTB and 81 patients with lung cancer were included in the current study ([Fig. 1](#f1-etm-0-0-4737){ref-type="fig"}). PTB diagnosis was established by pathological and acid-fast bacilli examinations. Briefly, tissue samples obtained from pulmonary lobectomy excision, percutaneous transthoracic needle biopsy or transbronchial lung biopsy were excised and fixed with 10% neutral buffered formalin at room temperature for 48 h. After fixation, the tissues were dehydrated and embedded in paraffin. Samples were then cut into 4 µm sections, stained with hematoxylin and eosin and examined using light microscopy (Olympus BX51; Olympus Corp. Tokyo, Japan). PTB lesions exhibited chronic granulomatous inflammation, with or without caseous necrosis. To further identified the mycobacteria in the tissue sections, acid-fast staining kits (Baso Biotechnology Co., Ltd., Wuhan, China) were used according to the manufacturer\'s protocol. Of the 22 patients with PTB, the mean age was 53.1±10.0 years (age range, 36--72 years) and there were more males (17/22, 77.3%) than females (5/22, 22.7%). The patients with lung cancer consisted of 41 males and 40 females with a mean age of 61±5.4 years (range, 33--79 years). The present study was approved by the Institutional Review Board of Chinese PLA General Hospital and written informed consents were waived as all the data were retrospectively reviewed and analyzed anonymously.

### Methods

The clinical data, radiological features, pathological results and therapeutic strategies of these patients were retrospectively reviewed. Clinical data included age, gender, smoking, medical history, histological type, tumor node metastasis (TNM) staging, performance status (PS) and levels of tumor markers. According to the 2015 World Health Organization (WHO) classifications of lung cancer ([@b17-etm-0-0-4737]), the histological types of lung cancer in the current study were determined. TNM staging of lung cancers was evaluated using the 7th edition of the American Joint Committee on Cancer/Union for International Cancer Control TNM staging system ([@b18-etm-0-0-4737]). The PS of lung cancers was assessed using the Eastern Cooperative Oncology Group scale ([@b19-etm-0-0-4737]). Tumor marker values in the serum including carcinoembryonic antigen (CEA), cytokeratin 19 fragments (CYFRA21-1), neuron-specific enolase (NSE) and cancer antigen (CA)-125 were detected by electrochemiluminescence immunoassay using the Roche COBAS E601 analyzer (Roche Diagnostics GmbH, Mannheim, Germany). Squamous cell carcinoma antigen (SCCAg) was assayed using a chemiluminescence microparticle immunoassay (Abbott ARCHITECT i2000SR immuno analyser; Abbott Pharmaceutical Co., Ltd., Lake Bluff, IL, USA). Serum concentrations of CEA (cat. no. 153910-01; Roche Diagnostics GmbH), CYFRA21-1 (cat. no. 146987-02; Roche Diagnostics GmbH), NSE (cat. no. 159459-01; Roche Diagnostics GmbH), CA-125 (cat. no. 16907902; Roche Diagnostics GmbH) and SCCAg (cat. no. 71111LP20; Abbott Pharmaceutical Co., Ltd.) were measured using kits according to the manufacturer\'s protocol. Levels of CEA \>5 ng/ml, CYFRA21-1 \>4 ng/ml, NSE \>24 ng/ml, CA-125 \>35 ng/ml, SCCAg \>1.8 ng/ml were considered to be abnormal according to the kit protocol. Radiological findings were based on the initial and rechecked CT or PET-CT manifestation of lesions prior to treatment. The location, largest size and abnormal pulmonary imaging of the lesions were recorded. A 64-row spiral CT with slice thickness of 1.5 mm, 5 mm or high resolution CT was used in all patients and PET-CT was used in a further 36 patients for diagnosis. PET-CT images were obtained 60 min after intravenous injection of FDG. All images were interpreted independently by two experienced physicians; at least one radiologist and another respiratory physician.

### Statistical analysis

SPSS 17.0 (SPSS, Inc., Chicago, IL, USA) was used to analyze the data. Quantitative variables were presented as the mean ± standard deviation whereas qualitative variables were presented as a percentage of the total number. The χ2 test or Fisher\'s exact test were used to compare clinical characteristics and imaging features between patients with PTB and those with lung cancer. Receiver operating characteristic (ROC) curves were analyzed to determine an SUV~max~ cut-off that would provide the optimal sensitivity and specificity for individuals undergoing PET-CT. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Clinical features

The clinical characteristics of the 22 patients with PTB are presented in [Table I](#tI-etm-0-0-4737){ref-type="table"}. A total of 18 patients (81.8%) were \<60 years old and 12 patients (54.5%) were smokers. A total of 12 patients (54.5%) had a history of diabetes in the 5 years preceding PTB diagnosis. Out of the 81 cases of lung cancer, the most common histological type was primary lung adenocarcinoma (n=69), followed by squamous cell carcinoma (n=9), pulmonary neuroendocrine carcinoma (n=2) and adenosquamous carcinoma (n=1). Furthermore, 32 (38.3%) patients with lung cancer were stage IA, 19 (23.5%) were stage IB, 25 (30.9%) were stage IIA or IIB and 5 (7.4%) were stage III or IV. Out of all patients with lung cancer, 54 (66.7%) underwent examination of levels of the tumor marker values CEA, CYFRA21-1, NSE, CA-125 and SCCAg prior to biopsy or operation. Based on the CT presentation mimicking lung cancer, 27 (33.3%) underwent operation directly without further examination of tumor marker values. Among these 54 cases, 29 (53.7%) abnormal results were obtained for CEA, 26 (48.1%) for CYFRA21-1, 13 (24.1%) for CA-125, 9 (16.7%) for SCCAg and 2 (3.7%) for NSE. Lung tumor markers were also investigated in the 22 patients with PTB, among which 4 patients exhibited abnormal values: 2 abnormal results were obtained for CYFRA21-1, 1 for CEA, 1 for SCCAg and 1 for NSE. The PS results of lung cancer were as follows: 23 (28.4%) lung cancers were 0, 40 (49.4%) were 1 and 18 (22.2%) were 2. The patients with PTB were compared to those with lung cancer and it was determined that the factors associated with PTB were an age \<60 years (P=0.003), being male (P=0.025) and the presence of diabetes (P\<0.001). No significant differences between patients with lung cancer and those with PTB were observed regarding smoking history (P=0.247).

### Chest CT characteristics of PTB

Chest CT findings demonstrated that PTB lesions involved the left upper lobe in 7 cases (31.8%), left lower lobe in 2 cases (9.1%), right upper lobe in 10 cases (45.5%) and right middle lobe in 3 cases (13.6%). No lesions involved the right lower lobe. The largest size ranged between 1 and 5 cm in diameter and the mean value was 2.51 cm. The suspected malignant signs of lung cancer occurred at PTB lesions and included spiculated margins in 18 cases (81.8%), lobulation in 15 cases (68.2%), blood vessel convergence signs in 4 cases (18.2%), pleural indentation in 8 cases (36.4%), ground-glass shadow in 3 cases (13.6%), cavity in 3 cases (13.6%) and vacuole in 5 cases (22.7%; [Table I](#tI-etm-0-0-4737){ref-type="table"}). Different malignant signs of lung cancer could be detected in a single patient ([Fig. 2](#f2-etm-0-0-4737){ref-type="fig"}). Considering the higher risk of malignancy, surgical wedge resection was performed in 17 patients, percutaneous transthoracic needle biopsy in 2 patients and transbronchial lung biopsy in 1 patient. Comparison of the assumed malignancy characteristics in patients with PTB against those with lung cancer ([Table II](#tII-etm-0-0-4737){ref-type="table"}) demonstrated that there were no significant differences between the 2 groups in terms of lobulation, blood vessel convergence signs, pleural indentation and ground-glass opacity (P\>0.05). However, there was a significant difference in the frequency of spiculated margins (P=0.002); patients with PTB had a significantly higher frequency of spiculated margins than patients with lung cancer.

### PET-CT findings

Of the 36 patients that underwent PET-CT, 9 patients (25%) were confirmed as PTB and 27 (75%) were diagnosed with lung cancer. Although an SUV~max~ \>2.5 was generally considered to be a diagnostic threshold strongly indicating malignancy, the SUV~max~ values in all 36 patients were \>2.5 ([Fig. 3](#f3-etm-0-0-4737){ref-type="fig"}). Comparatively, patients with PTB had a lower mean SUV~max~ than those with lung cancer; 5.99±2.66 vs. 10.09±5.38 (P=0.036; [Table II](#tII-etm-0-0-4737){ref-type="table"}). An ROC curve with a statistically significant area under the curve was obtained (0.759; 95% confidence interval 0.595--0.924; P=0.021). From the ROC curve, an SUV~max~ could be obtained that provided optimal sensitivity and specificity for the current study ([Fig. 4](#f4-etm-0-0-4737){ref-type="fig"}). With an SUV~max~ cut-off of 8.45, the sensitivity and specificity of PET-CT in distinguishing between PTB and lung cancer were 63.0 and 88.9%, respectively ([Fig. 4](#f4-etm-0-0-4737){ref-type="fig"}). These analyses indicated that an SUV~max~ cut-off of 8.45 improved the specificity of PET-CT for differentiating between PTB and lung cancer than the conventional SUV~max~ cut-off value of 2.5.

Discussion
==========

The present study illustrates the clinical and radiographic presentations of patients with asymptomatic PTB mimicking lung cancer. The clinical characteristics of patients with PTB were compared with those of patients with lung cancer and it was determined that the clinical associated risk factors associated with PTB included age \<60 years, being male and having a history of diabetes. The risk factors of PTB have been identified in previous studies and include overcrowding, poverty and undernutrition, alcohol misuse, diabetes, tobacco smoking and immune-suppressive therapy ([@b20-etm-0-0-4737],[@b21-etm-0-0-4737]). Thus, the WHO has recommended screening for diabetes in all patients diagnosed with TB ([@b22-etm-0-0-4737]). People with diabetes are three times more susceptible to active PTB than those without and it has been demonstrated that diabetes increases the severity of PTB and predicts poor outcomes in patients with PTB ([@b23-etm-0-0-4737]--[@b25-etm-0-0-4737]). One of the reasons for increased PTB susceptibility in patients with diabetes is that diabetes adversely affects host innate and adaptive immunity. This impairment of the immune system delays the recruitment of immunocytes, including macrophages and T helper 1 cells, to the lesions and reduces cytokine expression ([@b26-etm-0-0-4737]). Due to substantial increases in the prevalence of diabetes ([@b27-etm-0-0-4737]), effectively controlling PTB will become more of a challenge. This means that the coexistence of tuberculosis and diabetes presents a serious threat to global public health. Typical characteristics suggestive of PTB, including cough, hemoptysis, fever, night sweats and chest pain ([@b28-etm-0-0-4737]), were rare in patients recruited in the current study, making the early diagnosis of PTB more difficult. The results of the present study indicated that the incidence of diabetes in PTB was significantly higher than in lung cancer, thus a diagnosis of PTB should be taken into consideration for people with diabetes even if they present with CT or PET-CT images that suggest the presence of lung cancer.

Tumor markers have been extensively used to distinguish patients with lung cancer from those with benign diseases. High levels of tumor markers are considered to indicate the presence of lung cancer rather than nonmalignant diseases ([@b29-etm-0-0-4737]). CEA, cancer antigen 125, CYFRA 21-1 and SCCAg are reliable markers in the diagnosis of non-small cell lung cancer whereas pro-gastrin-releasing peptide and NSE are commonly used to diagnose small-cell lung cancer ([@b30-etm-0-0-4737]--[@b32-etm-0-0-4737]). However, it has been reported that abnormal concentrations of tumor markers are detected in benign diseases, including PTB ([@b33-etm-0-0-4737],[@b34-etm-0-0-4737]). In the current study, abnormal levels of CEA, CYFRA21-1, NSE and SCCAg were identified in patients with PTB, indicating that positive tumor markers are not specific for lung cancer.

It has been well documented that various morphological features, including spiculated margins, lobulation, blood vessel convergence signs, pleural indentation, ground-glass opacity and cavity with a thick and irregular wall, detected by chest CT scans, are usually associated with malignancy ([@b35-etm-0-0-4737]--[@b37-etm-0-0-4737]). By contrast, nodules with smooth margins, bronchus signs and a round shape were considered to be predictors of benign lesions. A recent study analyzing 84 patients diagnosed with PTB by percutaneous transthoracic needle biopsy, identified nodules with spiculated margins in 26 cases and lobulation in 8 ([@b38-etm-0-0-4737]). In the current study, morphological characteristics of PTB meant that it exhibited one or more signs of malignancy. Furthermore, it was determined that patients with asymptomatic PTB had a significantly higher frequency of spiculated margins than patients with lung cancer. Consequently, there are overlaps between PTB and lung cancer on the chest CT. Although morphological characteristics may be helpful in identifying whether lesions are PTB or lung cancer, the results may not always be conclusive.

As a precise imaging tool, PET-CT has been widely used to distinguish between malignant and benign lesions ([@b39-etm-0-0-4737]). PET-CT imaging relies on radiopharmaceutical FDG accumulation in increased glucose metabolic areas, so may be used to detect active TB and evaluate the response to anti-tuberculosis therapy in patients ([@b40-etm-0-0-4737]). Generally, malignant lesions have a significantly higher FDG uptake than benign lesions. The SUV~max~ cut-off of 2.5 was considered to be a diagnostic threshold for differentiating benign and malignant lesions ([@b41-etm-0-0-4737]). However, TB has an extensive range of SUVs, which may be due to its varying degree of granulomatous inflammation. It is not uncommon for TB lesions have an SUV~max~ \>2.5, thus false-positive diagnoses may be made, particularly in tuberculosis-endemic areas. In clinical practice, false-positive diagnoses can also result from the presence of other benign conditions including sarcoidosis and rheumatoid nodule ([@b42-etm-0-0-4737]). The utility of PET-CT in the evaluation of pulmonary lesions has been assessed, and it has been suggested that an SUV~max~ of 5.0 may be a more appropriate cut-off value in areas with a high prevalence of TB ([@b43-etm-0-0-4737]). Hence, the diagnostic accuracy of PET-CT in TB-endemic areas was reduced using the conventional SUV~max~ cut-off value. From the ROC curve constructed in the current study, it was suggested that an SUV~max~ cut-off of 8.45 may be more effective at distinguishing between PTB and lung cancer in patients. This cut-off value is much higher than the more commonly used threshold of 2.5. Although an SUV~max~ cut-off value of 8.45 may result in lung cancers with low metabolic activity being falsely reported as PTB, it may prompt clinicians to be more cautious when interpreting results from PET-CT. Although a biopsy is able to differentiate between PTB and lung cancer, it is not technically possible for some patients. To increase the diagnostic accuracy in the assessment of asymptomatic PTB, SUV values as well as other clinical and radiological results should be integrated. After anti-tuberculosis therapy, high SUV values may rapidly decrease and clinical symptoms are ameliorated in PTB patients ([@b44-etm-0-0-4737]). In contrast, malignant lesions are unlikely to change after anti-tuberculosis therapy. Therefore, a biopsy as well as the clinical and radiological changes resulting from anti-tuberculosis treatment response may be used to differentiate these two similar diseases.

In conclusion, patients with asymptomatic PTB mimicking lung cancer usually exhibit abnormal chest CT presentation and increased glucose uptake, which is extremely similar to lung cancer. Compared with lung cancer, the factors associated with asymptomatic PTB include an age of \<60 years, being male, having diabetes, spiculated margins and a lower SUV~max~. The optimal cut-off level was SUV~max~ 8.45 for discriminating between asymptomatic PTB and lung cancer. Comprehensively considering the associated risk factors and recognizing the various imaging manifestations of this uncommon PTB may increase the diagnostic accuracy of asymptomatic PTB. An increased threshold of SUV~max~ may markedly improve the specificity of PET-CT of diagnosing PTB in TB-endemic area and further multicenter studies involving larger samples sizes are required.
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![Representative chest computed tomography presentations of asymptomatic pulmonary tuberculosis mimicking lung cancer. Lesions in the 4 cases (from 4 different patients) exhibited the suspected malignant signs of lung cancer including (A) spiculated margins, pleural indentation (B) lobulation, spiculated margins, pleural indentation (C) blood vessel convergency, spiculated margain, pleural indentation (D) pleural indentation and lobulation.](etm-14-03-2180-g01){#f2-etm-0-0-4737}

![PET-CT imaging of asymptomatic pulmonary tuberculosis mimicking lung cancer. PET-CT revealed a 2.3×1.3 cm lesion with malignancy features and the SUV~max~ was 7.7 in the right upper lobe. PET-CT, ^18^F-fludeoxyglucose-positron emission tomography-computer tomography; SUV~max~, maximum standard uptake value.](etm-14-03-2180-g02){#f3-etm-0-0-4737}

![The ROC curve represented the capability of SUV~max~ to differentiate PTB from lung cancer. ROC, receiver operating characteristic; SUV~max~, the maximum standard uptake value.](etm-14-03-2180-g03){#f4-etm-0-0-4737}

###### 

Clinical characteristics and imaging features of the 22 patients with PTB.

  No./age/sex   Smoking (years/cigarettes per day)   Diabetes   Largest size (cm)   Location of lesion   Type of biopsy        CT presentation                                                    PET (SUV~max~)
  ------------- ------------------------------------ ---------- ------------------- -------------------- --------------------- ------------------------------------------------------------------ ----------------
  1/41/M        20/20                                Yes            2.8             RUL                  Pulmonary lobectomy   Ground-glass shadow, spiculated margin, lobulation, vacuole            2.65
  2/41/M        20/40                                Yes            2.5             RUL                  Pulmonary lobectomy   Spiculated margin, vacuole                                             8.4
  3/64/M        20/60                                Yes        5                   RUL                  Pulmonary lobectomy   Spiculated margin, lobulation, pleural indentation                 --
  4/51/M        30/50                                Yes            2.5             RUL                  Pulmonary lobectomy   Spiculated margin, lobulation                                      --
  5/43/F        No                                   No             2.6             RML                  Pulmonary lobectomy   Spiculated margin, blood vessel convergency                        --
  6/50/M        No                                   Yes            1.2             LUL                  PTNB                  Ground-glass shadow                                                --
  7/59/M        30/20                                Yes        2                   LUL                  Pulmonary lobectomy   Pleural indentation, vacuole                                       --
  8/55/F        No                                   No             1.6             RUL                  TBLB                  Spiculated margin, lobulation                                      10.9
  9/61/M        15/40                                Yes            3.2             RML                  Pulmonary lobectomy   Spiculated margin, lobulation, pleural indentation, cavity         --
  10/57/M       No                                   Yes            2.3             RUL                  Pulmonary lobectomy   Spiculated margin, lobulation, pleural indentation                     7.7
  11/68/M       50/20                                Yes        4                   LUL                  Pulmonary lobectomy   Spiculated margin, lobulation, pleural indentation                 --
  12/39/M       No                                   No             1.3             LUL                  Pulmonary lobectomy   Spiculated margin, lobulation                                          5.4
  13/72/M       No                                   No         1                   RML                  Pulmonary lobectomy   Spiculated margin, lobulation                                          3.16
  14/63/M       35/20                                Yes            1.8             LUL                  Pulmonary lobectomy   Spiculated margin, pleural indentation, blood vessel convergency   --
  15/51/F       No                                   Yes        3                   LUL                  Pulmonary lobectomy   Spiculated margin, lobulation                                          4.2
  16/59/M       No                                   Yes            2.5             LLL                  Pulmonary lobectomy   Spiculated margin, lobulation, cavity, ground-glass shadow         --
  17/56/M       40/20                                No             1.5             LLL                  Pulmonary lobectomy   Spiculated margin, lobulation, blood vessel convergency            --
  18/41/F       40/20                                No             3.5             RUL                  Pulmonary lobectomy   Spiculated margin, vacuole                                             6.5
  19/59/M       No                                   No             2.7             RUL                  PTNB                  Spiculated margin, lobulation, cavity                              --
  20/36/F       No                                   No             2.4             RUL                  Pulmonary lobectomy   Spiculated margin, pleural indentation                             --
  21/47/M       10/20                                No             3.5             RUL                  Pulmonary lobectomy   Lobulation, vacuole                                                --
  22/57/M       20/40                                No             2.5             LUL                  Pulmonary lobectomy   Lobulation, blood vessel convergency, pleural indentation          5.02

No, patient number; M, male; F, female; SUV~max~, maximum standard uptake value; LUL, left upper lobe; LLL, left lower lobe; RUL, right upper lobe; RML, right middle lobe; PTNB, percutaneous transthoracic needle biopsy; TBLB, transbronchial lung biopsy; PET, ^18^F-fludeoxyglucose-positron emission tomography.

###### 

Clinical and radiological finding in patients with PTB vs. those with lung cancer.

                               Total, no. (%)   Tuberculosis, no. (%)   Lung cancer, no. (%)   P-value
  ---------------------------- ---------------- ----------------------- ---------------------- -------------------------------------------------------
  No.                          103              22                      81                     
  Age, years                                                                                   0.003^[a](#tfn2-etm-0-0-4737){ref-type="table-fn"}^
    \<60                         55             18                      37                     
    ≥60                          48               4                     44                     
  Sex                                                                                          0.025^[a](#tfn2-etm-0-0-4737){ref-type="table-fn"}^
    Male                         58             17                      41                     
    Female                       45               5                     40                     
  Smoking history                                                                              0.247
    Smoker                       45             12                      33                     
    Never smoked                 58             10                      48                     
  Underlying diseases                                                                          \<0.001^[a](#tfn2-etm-0-0-4737){ref-type="table-fn"}^
    Diabetes                     25             12                      13                     
    Non-diabetes                 78             10                      68                     
  Location of lesion                                                                           0.175
    Upper lobe                   67             17                      50                     
    Others                       36               5                     31                     
  Largest size (cm)                                                                            0.210
    \<2                          40               6                     34                     
    ≥2                           63             16                      47                     
  CT presentation                                                                              
    Spiculated margin            54             18                      36                     0.002^[a](#tfn2-etm-0-0-4737){ref-type="table-fn"}^
    Lobulation                   63             15                      48                     0.446
    Ground-glass shadow          31               3                     28                     0.058
    Pleural indentation          38               8                     30                     0.922
    Blood vessel convergency     25               4                     21                     0.452
    Cavity                       8                3                       5                    0.477
    Vacuole                      13               5                       8                    0.212
  PET (SUV~max~)                                                                               
    Mean ± SD                  9.06±5.13        5.99±2.66               10.09±5.38             0.036^[a](#tfn2-etm-0-0-4737){ref-type="table-fn"}^

P\<0.05 patients with PTB vs. patients with lung cancer. No, number; PTB, pulmonary tuberculosis; CT, computed tomography; PET, ^18^F-fludeoxyglucose-positron emission tomography/computer tomography; SUV~max~, maximum standard uptake value; SD, standard deviation.
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